Our Services
Medical Information
Helpful Resources
Published on: 7/2/2026
GLP-1 receptor agonists support weight loss by reducing appetite, slowing gastric emptying, and improving blood sugar regulation. For best results, they are used with personalized nutrition, exercise, and behavioral support under medical supervision. A structured program also includes dose adjustments, metabolic monitoring, and multidisciplinary goal setting to maximize safety and effectiveness.
Because eligibility, side effects, and outcomes vary widely from person to person, understanding your own health picture is the critical first step. If you're experiencing symptoms related to weight, blood sugar, or digestion, take a free, instant, online symptom check to clarify what may be going on and guide your next steps with confidence.
Reviewed for medical accuracy: 07/02/2026
Medical weight loss programs have evolved dramatically over the past decade. One of the most significant advances is the use of GLP-1 receptor agonists (commonly called "GLP-1s") alongside traditional diet, exercise, and behavioral support. This article explains what GLP-1s are, how they work, and why they're most effective when integrated into a holistic program overseen by a healthcare team.
GLP-1 (glucagon-like peptide-1) receptor agonists are medications originally developed to treat type 2 diabetes. They mimic a hormone your intestines release after eating. Key actions include:
Common GLP-1 medications include liraglutide, semaglutide, and dulaglutide. While each has unique dosing schedules, they share core benefits for weight management.
GLP-1s alone aren't a magic bullet. Their real power comes when they're part of a broader, medically supervised plan:
Multidisciplinary Approach
Data-Driven Monitoring
Goal Setting and Education
GLP-1s can be considered for adults who:
They're not recommended for people with certain conditions (e.g., personal/family history of medullary thyroid carcinoma) or pregnant women. Always discuss your full medical history with your doctor.
Nutrition
Physical Activity
Behavioral Support
When GLP-1s are part of a structured medical weight loss program, patients often see:
GLP-1s are generally well tolerated, but some people experience:
To minimize side effects:
If you experience life-threatening symptoms—such as severe abdominal pain, rapid heart rate, or unusual mood changes—seek medical attention right away.
Not sure if GLP-1 therapy or another intervention is right for you? Before your next doctor's appointment, try using a Medically approved LLM Symptom Checker Chat Bot to evaluate your symptoms and better understand whether medical weight loss might be appropriate for your situation.
Self-prescribing weight-loss drugs or following online "hacks" can be risky. A medical weight loss program ensures:
Always keep your care team informed about new symptoms, medication changes, or personal challenges that may affect your progress.
This information is intended to help you understand how GLP-1s fit into medical weight loss programs. It's not a substitute for personalized medical advice. If you're experiencing serious symptoms or considering GLP-1 therapy, please speak to a doctor or qualified healthcare professional.
—End of article—
(References)
* Wilding JP, Batterham RL, Calanna S, Van Gaal MA, McGowan BD, Rosenstock S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.
* Srivastava A, Grewal P, Al-Shaer G, Ankar M, Al-Badri M. Pharmacological Management of Obesity: An Update on the Efficacy and Safety of Current and Emerging Agents. Drugs. 2023 Mar;83(4):303-328. doi: 10.1007/s40265-023-01832-7. Epub 2023 Feb 15. PMID: 36792759.
* Al-Shawwa K, Al-Jammal M, Barakat M, Fares WH, Al-Badri M, Grewal P. A multidisciplinary approach to managing obesity in primary care: a review of current evidence and future perspectives. Curr Opin Endocrinol Diabetes Obes. 2022 Oct 1;29(5):470-476. doi: 10.1097/MED.0000000000000762. Epub 2022 Jul 14. PMID: 35833446.
* Hussein MA, Al-Badri M, Abusnana S, Al-Fares M, Fares WH, Grewal P. Cardiovascular and renal outcomes with GLP-1 receptor agonists in patients with type 2 diabetes and obesity: a narrative review. Obes Rev. 2023 Oct;24(10):e13627. doi: 10.1111/obr.13627. Epub 2023 Jul 11. PMID: 37434945.
* Jastreboff AM, Rosenstock S, Van Gaal MA, McGowan BD, Wilding JP, Batterham RL, et al. GLP-1 receptor agonists for weight management: a review of current evidence and future directions. Obes Rev. 2023 Apr;24(4):e13554. doi: 10.1111/obr.13554. Epub 2022 Dec 19. PMID: 36536965.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.